A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control
Epistemonikos ID: 332669f59e55aabc717662424e80f5953087989d
First added on: May 11, 2024